SCHEMBL25546332

SCHEMBL25546332

COc1cc(C)cc(-c2nc(Cl)sc2CC(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.41
DHFR P00374 1/20 0.33
ROS1 P08922 2/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
TP53 P04637 2/20 0.32
CYP1A1 P04798 2/20 0.32
CYP1B1 Q16678 2/20 0.32
LMNA P02545 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
KMT2A Q03164 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545944 0.92 FBP1 (0.44) FBP1MAOAMAOBCYP1A1CYP1B1
SCHEMBL25546362 0.87 FBP1 (0.42) FBP1KMT2A
SCHEMBL25546318 0.83 FBP1 (0.38) FBP1KMT2AADORA2AADORA1ALDH1A1
SCHEMBL25545933 0.82 TDP1 (0.44) FBP1TP53LMNAADORA2AADORA1
SCHEMBL25556546 0.80 FBP1 (0.42) FBP1CYP1A1CYP1B1LMNAKMT2A
SCHEMBL25546325 0.76 S1PR1 (0.50) FBP1DHFRLMNAALDH1A1
SCHEMBL25545941 0.75 LMNA (0.48) FBP1TP53LMNAKMT2AALDH1A1
SCHEMBL25545928 0.75 FBP1 (0.42) FBP1MAOAMAOBTP53LMNA
SCHEMBL25545932 0.74 FBP1 (0.44) FBP1LMNAALDH1A1
SCHEMBL25546361 0.73 FBP1 (0.43) FBP1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885DHFR 3694/4885ROS1 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.